Therapeutic radiopharmaceutical developer Algeta has inked an $800 million agreement with Bayer for the development and commercialization of its Alpharadin alpha-emitting pharmaceutical for treating bone metastases.
Based on radium-223, Alpharadin is currently being evaluated in a global, phase III trial in men with hormone-refractory prostate cancer that has spread to the bone. Algeta of Oslo, Norway, and Bayer of Leverkusen, Germany, will jointly develop Alpharadin, with Bayer contributing a substantial portion of the costs of future development and fully funding any additional late-stage trials.
Algeta will retain an option for copromotion and profit-sharing in the U.S. The firm will receive $61 million in cash upfront, followed by development, production, and commercialization milestones. It will be responsible for manufacturing and supplying Alpharadin.
Related Reading
Bayer to settle 'several' NSF contrast cases, April 17, 2009
Bayer partners with Hamamatsu, January 12, 2009
Bayer Schering, Epix to end Vasovist partnership, September 4, 2008
Bayer awarded Amerinet deal, April 14, 2008
New promise for therapeutic radiopharmaceuticals, June 2, 2006
Copyright © 2009 AuntMinnie.com
![Overview of the study design. (A) The fully automated deep learning framework was developed to estimate body composition (BC) (defined as subcutaneous adipose tissue [SAT] in liters; visceral adipose tissue [VAT] in liters; skeletal muscle [SM] in liters; SM fat fraction [SMFF] as a percentage; and intramuscular adipose tissue [IMAT] in deciliters) from MRI. The fully automated framework comprised one model (model 1) to quantify different BC measures (SAT, VAT, SM, SMFF, and IMAT) as three-dimensional (3D) measures from whole-body MRI scans. The second model (model 2) was trained to identify standardized anatomic landmarks along the craniocaudal body axis (z coordinate field), which allowed for subdividing the whole-body measures into different subregions typically examined on clinical routine MRI scans (chest, abdomen, and pelvis). (B) BC was quantified from whole-body MRI in over 66,000 individuals from two large population-based cohort studies, the UK Biobank (UKB) (36,317 individuals) and the German National Cohort (NAKO) (30,291 individuals). Bar graphs show age distribution by sex and cohort. BMI = body mass index. (C) After the performance assessment of the fully automated framework, the change in BC measures, distributions, and profiles across age decades were investigated. Age-, sex-, and height-adjusted body composition reference curves were calculated and made publicly available in a web-based z-score calculator (https://circ-ml.github.io).](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/05/body-comp.XgAjTfPj1W.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
